United Therapeutics Corporation revenue by year
Over the 10 fiscal years shown, revenue went from $1.60B (year ended Dec 31, 2016) to $3.18B (year ended Dec 31, 2025), a compound annual growth rate of 8.0%. The fastest growth was +23.6% in the year ended Dec 31, 2024; the weakest year was −11.0% (year ended Dec 31, 2019).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $3.18B | +10.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2024 | $2.88B | +23.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2023 | $2.33B | +20.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 25, 2026 |
| Dec 31, 2022 | $1.94B | +14.9% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 26, 2025 |
| Dec 31, 2021 | $1.69B | +13.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 21, 2024 |
| Dec 31, 2020 | $1.48B | +2.4% | Revenues | 10-K filed Feb 24, 2021 |
| Dec 31, 2019 | $1.45B | −11.0% | Revenues | 10-K filed Feb 24, 2021 |
| Dec 31, 2018 | $1.63B | −5.7% | Revenues | 10-K filed Feb 24, 2021 |
| Dec 31, 2017 | $1.73B | +7.9% | Revenues | 10-K filed Feb 26, 2020 |
| Dec 31, 2016 | $1.60B | +9.1% | Revenues | 10-K filed Feb 27, 2019 |
United Therapeutics Corporation reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Jun 30, 2026 | $783.30M | −1.9% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2026 | $781.50M | −1.6% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2025 | $799.50M | +6.8% | 10-Q filed Oct 29, 2025 |
| 3 months ended Jun 30, 2025 | $798.60M | +11.7% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2025 | $794.40M | +17.2% | 10-Q filed May 6, 2026 |
| 3 months ended Sep 30, 2024 | $748.90M | +22.9% | 10-Q filed Oct 29, 2025 |
| 3 months ended Jun 30, 2024 | $714.90M | +19.8% | 10-Q filed Jul 30, 2025 |
| 3 months ended Mar 31, 2024 | $677.70M | +33.7% | 10-Q filed Apr 30, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 1082554 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.